Bessemer Group
HARP

Bessemer Group’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Bessemer Group’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,180
Closed -$528K – 1735
2020
Q2 		$528K Buy
+3,180
New +$496K ﹤0.01% 955

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bessemer Group's HARP Position: Q3 2020 in Review

Bessemer Group sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2020, closing a stake of 3,180 shares — an estimated $528K sold.

Bessemer Group first reported a position in HARP in Q2 2020 and held it in 1 quarter. The position peaked at $528K in Q2 2020. 79 funds tracked by Wall St. Rank hold HARP as of Q3 2020.

  • Bessemer Group reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Bessemer Group sold 3,180 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $528K.
  • Bessemer Group first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Bessemer Group's Harpoon Therapeutics, Inc. Common Stock position peaked at $528K in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.